Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic | Zendy

Richard J. Hall | Zendy; Matthew Peacey | Zendy; Jacqui Ralston | Zendy; Danielle J de Joux | Zendy; Judy Bocacao | Zendy; Mackenzie Nicol | Zendy; Molly Ziki | Zendy; Wendy Gunn | Zendy; Jing Wang | Zendy; Q. Sue Huang | Zendy

Open Access

Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic

Author(s) -

Richard J. Hall,

Matthew Peacey,

Jacqui Ralston,

Danielle J de Joux,

Judy Bocacao,

Mackenzie Nicol,

Molly Ziki,

Wendy Gunn,

Jing Wang,

Q. Sue Huang

Publication year - 2012

Publication title -

western pacific surveillance response journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.515

H-Index - 16

eISSN - 2094-7313

pISSN - 2094-7321

DOI - 10.5365/wpsar.2012.3.3.002

Subject(s) - virology , pandemic , oseltamivir , virus , pandemic influenza , covid-19 , biology , influenza a virus , medicine , infectious disease (medical specialty) , disease

Oseltamivir (Tamiflu®) is an important pharmaceutical intervention against the influenza virus. The importance of surveillance for resistance to oseltamivir has been highlighted by two global events: the emergence of an oseltamivir-resistant seasonal influenza A(H1N1) virus in 2008, and emergence of the influenza A(H1N1)pdm09 virus in 2009. Oseltamivir is a prescription medicine in New Zealand, but more timely access has been provided since 2007 by allowing pharmacies to directly dispense oseltamivir to patients with influenza-like illness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research